NeuroRx, NeuroRx, Wilmington-based clinical stage biopharma company has retained J.P. Morgan as financial advisor.
The company is developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation & Behavior (ASIB).
NeuroRx will begin enrolling patients shortly in a Phase 2b/3 study targeting severe bipolar depression in patients with ASIB.
The U.S. Food and Drug Administration awarded FAST TRACK designation to this investigational drug regimen in August, 2017.
There currently is no approved drug therapy for bipolar depression in patients with Acute Suicidal Ideation and Behavior, the only FDA-approved treatment is electroconvulsive therapy (ECT). Antidepressants typically bear a warning about their potential to increase the risk of suicide.
Jonathan Javitt, M.D., founder and CEO will provide a company update at the upcoming annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 10.